natgillin/translations-raw huggingface dataset:
For the full list of all side effects and restrictions with Liprolog, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Liprolog glejte navodilo za uporabo.
Liprolog 100 units/ml may also be given by continuous infusion using an insulin pump or into a vein. 
Zdravilo Liprolog 100 enot/ml se lahko daje tudi s kontinuirano infuzijo z insulinsko črpalko ali v veno.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Liprolog, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Why has Liprolog been approved? 
Zakaj je bilo zdravilo Liprolog odobreno?
Liprolog and Humulin R had a similar effect on the control of diabetes, as measured by HbA1c and fasting glucose levels. 
Zdravili Liprolog in Humulin R sta podobno učinkovali na nadzor sladkorne bolezni, kar so pokazale ravni HbA1c in ravni glukoze na tešče.
The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled, and ‘fasting' blood glucose levels (measured when the patient had not eaten for at least eight hours). 
V študijah so merili raven snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako učinkovito je raven glukoze v krvi nadzorovana, in glukoze v krvi bolnika na tešče (izmerjene vsaj osem ur po zadnjem obroku).
Liprolog 200 units/ml must only be injected under the skin, using the KwikPen device in which it is supplied. 
Zdravilo Liprolog 200 enot/ml je treba injicirati pod kožo s peresnikom KwikPen, v katerem je pripravljeno za uporabo.
The Committee for Medicinal products for Human Use (CHMP) decided that Liprolog's benefits are greater than its risks for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis, and for the initial stabilisation of diabetes mellitus. 
Odbor za zdravila za humano uporabo (CHMP) je zaključil, da so koristi zdravila Liprolog pri zdravljenju bolnikov s sladkorno boleznijo, ki potrebujejo insulin za vzdrževanje normalne homeostaze glukoze, pa tudi za začetno stabilizacijo sladkorne bolezni, večje od z njim povezanih tveganj.
The Liprolog range is comprised of fast-acting insulin solutions (Liprolog), longer-acting insulin suspensions (Liprolog Basal), and combinations of both in various proportions (Liprolog Mix): 
Izdelki Liprolog vsebujejo raztopine insulinov s hitrim delovanjem (Liprolog), suspenzije insulinov z dolgotrajnejšim delovanjem (Liprolog Basal) ter kombinacije obeh v različnih razmerjih (Liprolog Mix):
Liprolog is a replacement insulin which is very similar to the insulin made by the body. 
Zdravilo Liprolog je nadomestni insulin, ki je zelo podoben insulinu, ki ga proizvaja telo.
• Liprolog Basal: insulin lispro protamine suspension; 
• Liprolog Basal: suspenzija insulina lispro-protamin;
The effectiveness of Liprolog was compared with that of Humulin R (a soluble recombinant DNA human insulin), when added to long-acting insulins given once or twice a day. 
Učinkovitost zdravila Liprolog so primerjali z učinkovitostjo zdravila Humulin R (topnega humanega insulina, nastalega s pomočjo tehnologije rekombinantne DNK), pri čemer so obe zdravili dodajali insulinom z dolgotrajnim delovanjem, ki se dajejo enkrat do dvakrat dnevno.
Insulin lispro is available as Liprolog in the soluble form, which acts more or less immediately after injection, and as Liprolog Basal in the ‘protamine suspension' form, which is absorbed much more slowly so that it works for longer. 
Insulin lispro je v zdravilu Liprolog na voljo v topni obliki, zaradi česar večinoma učinkuje takoj po injekciji, v zdravilu Liprolog Basal pa v obliki suspenzije protamina, ki se absorbira veliko počasneje in zato učinkuje dlje.
Liprolog is used to treat patients who have diabetes and need insulin to keep their blood glucose (sugar) level controlled, including patients whose diabetes has just been diagnosed. 
Zdravilo Liprolog se uporablja za zdravljenje odraslih in otrok s sladkorno boleznijo, ki potrebujejo insulin za nadzor sladkorja v krvi, vključno z bolniki, katerim je bila sladkorna bolezen šele diagnosticirana.
Liprolog can be used with a longer-acting insulin or with sulphonylureas (a group of diabetes medicines that are taken by mouth). 
Zdravilo Liprolog se lahko uporablja z insulinom z daljšim delovanjem ali s sulfonilsečninami (skupino peroralnih zdravil za zdravljenje sladkorne bolezni).
Liprolog Mix, Liprolog Basal and Liprolog 200 units/ml should never be given into a vein. 
Zdravil Liprolog Mix, Liprolog Basal in Liprolog 200 enot/ml se ne sme dajati v veno.
How has Liprolog been studied? 
Kako je bilo zdravilo Liprolog raziskano?
Liprolog is supplied in vials, cartridges and prefilled pens (Liprolog KwikPen). 
Na voljo je v vialah, vložkih ali napolnjenih injekcijskih peresnikih (Liprolog KwikPen).
Liprolog, Liprolog Basal and Liprolog Mix may be given by injection under the skin of the upper arm, thigh, buttock or abdomen (tummy). 
Zdravila Liprolog, Liprolog Basal in Liprolog Mix se dajejo pod kožo z injekcijo v nadlaket, stegno, zadnjico ali trebuh.
What is Liprolog? 
Kaj je zdravilo Liprolog?
What is Liprolog used for? 
Za kaj se zdravilo Liprolog uporablja?
Liprolog contains the active substance insulin lispro. 
Zdravilo Liprolog vsebuje zdravilno učinkovino insulin lispro.
How is Liprolog used? 
Kako se zdravilo Liprolog uporablja?
How does Liprolog work? 
Kako zdravilo Liprolog deluje?
It can also be used on its own in: 
Uporablja se lahko tudi samostojno pri:
This was converted into a full marketing authorisation on 20 November 2018. 
To je bilo 20. novembra 2018 spremenjeno v običajno dovoljenje za promet.
Further information on Venclyxto can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Venclyxto. 
Nadaljnje informacije o zdravilu Venclyxto so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Venclyxto.
Regarding safety, the medicine's side effects are considered acceptable. 
Kar zadeva varnost, neželeni učinki zdravila veljajo za sprejemljive.
The starting dose is 20 mg daily and the dose is gradually increased over 5 weeks to 400 mg. 
Začetni odmerek je 20 mg na dan, ta pa se v obdobju pet tednov postopoma povečuje do 400 mg.
Although there is a risk of tumour lysis syndrome, a complication that occurs when the cancer cells are being destroyed too quickly, this risk can be contained through preventive measures, such as increasing the dose gradually or reducing the dose, if needed. 
Čeprav obstaja tveganje za sindrom tumorske lize, tj. zaplet, ki se pojavi, kadar se rakave celice prehitro uničujejo, se to tveganje lahko obvlada s preventivnimi ukrepi, kot sta postopno povečevanje odmerka ali zmanjšanje odmerka, če je potrebno.
Venclyxto received a conditional marketing authorisation valid throughout the EU on 5 December 2016. 
Za zdravilo Venclyxto je bilo 5. decembra 2016 izdano pogojno dovoljenje za promet, veljavno po vsej EU.
If the patient experiences certain side effects, treatment may be stopped temporarily or the dose reduced. 
Če bolnik občuti določene neželene učinke, bo zdravljenje morda treba začasno prekiniti ali zmanjšati odmerek.
What measures are being taken to ensure the safe and effective use of Venclyxto? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Venclyxto?
Patients in this second study had all previously taken B-cell receptor pathway inhibitors. 
Vsi bolniki v tej drugi študiji so predhodno prejemali zaviralce receptorske poti celic B.
This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. 
Ta beljakovina je v velikih količinah prisotna v rakavih celicah KLL, kjer celicam pripomore k daljšemu preživetju v telesu in jih naredi odporne proti zdravilom za zdravljenje raka.
The European Medicines Agency decided that Venclyxto's benefits outweigh its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da koristi zdravila Venclyxto odtehtajo njegova tveganja in da se lahko odobri za uporabo v EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Venclyxto have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Venclyxto upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
A high response rate was also seen in patients whose previous treatment with ibrutinib or idelalisib failed. 
Poleg tega so visoko stopnjo odziva opazili tudi pri bolnikih, pri katerih je bilo predhodno zdravljenje z ibrutinibom ali idelalisibom neuspešno.
As for all medicines, data on the use of Venclyxto are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Venclyxto stalno spremljajo.
In these patients, Venclyxto is used when medicines known as B-cell receptor pathway inhibitors (ibrutinib and idelalisib) are not suitable or have failed. 
Pri teh bolnikih se zdravilo Venclyxto uporablja, kadar zdravila, znana kot zaviralci receptorske poti celic B (ibrutinib in idelalisib), niso primerna ali niso bila uspešna.
Side effects reported with Venclyxto are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Venclyxto, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Why is Venclyxto authorised in the EU? 
Zakaj je zdravilo Venclyxto odobreno v EU?
In another study of 127 patients with or without 17p deletion or TP53 mutation, the response rate was 70%. 
V drugi študiji s 127 bolniki z delecijo 17p ali mutacijo TP53 ali brez njiju je bila stopnja odziva 70 %.
For more information about using Venclyxto, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Venclyxto glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
A high proportion of patients respond to Venclyxto after other treatments have failed or are unsuitable. 
Na zdravilo Venclyxto se odzove velik delež bolnikov, kadar druga zdravila niso uspešna ali niso primerna.
When Venclyxto is used on its own, treatment should continue for as long as the patient improves or remains stable and the side effects are tolerable. 
Kadar se zdravilo Venclixto uporablja samostojno, je treba zdravljenje nadaljevati tako dolgo, dokler se stanje bolnika izboljšuje oziroma ostaja stabilno in dokler so neželeni učinki znosni.
Venclyxto should be taken for 24 months from day 1 of the first cycle of rituximab. 
Zdravilo Venclixto je treba jemati 24 mesecev od prvega dne v prvem ciklusu zdravljenja z rituksimabom.
In a main study of 107 previously treated patients with CLL and 17p deletion, 75% responded partially or completely to Venclyxto. 
V glavni študiji s 107 predhodno zdravljenimi bolniki s KLL in delecijo 17p se jih je 75 % delno ali popolnoma odzvalo na zdravilo Venclyxto.
Venclyxto is available as tablets (10, 50 and 100 mg) to be taken by mouth once a day with a meal. 
Zdravilo Venclyxto je na voljo v obliki tablet (10 mg, 50 mg in 100 mg), ki se jemljejo peroralno enkrat na dan med obrokom.
An overview of Venclyxto and why it is authorised in the EU 
Pregled zdravila Venclyxto in zakaj je odobreno v EU
Venclyxto can be used in combination with rituximab (another cancer medicine) in patients who have received at least one previous treatment. 
Zdravilo Venclyxto se lahko uporablja v kombinaciji z rituksimabom (drugim zdravilom za zdravljenje raka) pri bolnikih, ki so bili zdravljeni že vsaj enkrat.
What is Venclyxto and what is it used for? 
Kaj je zdravilo Venclyxto in za kaj se uporablja?
By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down the progression of the disease. 
Venetoklaks z vezavo na beljakovino Bcl-2 in zaviranjem njenega delovanja povzroči odmrtje rakavih celic in tako upočasni napredovanje bolezni.
• patients with particular genetic changes (17p deletion or TP53 mutation) that make them unsuitable for chemo-immunotherapy (a type of cancer treatment). 
• bolnikih z določenimi genskimi spremembami (delecijo 17p ali mutacijo TP53), zaradi katerih niso primerni za kemoimunoterapijo (vrsta zdravljenja raka).
Venclyxto should be started and supervised by a doctor with experience of cancer medicines and can only be obtained with a prescription. 
Zdravljenje z zdravilom Venclyxto mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravili za zdravljenje raka, predpisovanje in izdaja zdravila pa je le na recept.
• patients who do not have these genetic changes after treatments with chemo-immunotherapy and a B-cell receptor pathway inhibitor have both failed. 
• bolnikih brez teh genskih sprememb, pri katerih zdravljenje s kemoimunoterapijo in zaviralcem receptorske poti celic B ni bilo uspešno.
Another study in 389 patients with CLL who received at least one previous treatment showed that patients treated with Venclyxto plus rituximab lived longer without their disease getting worse (progression-free survival) than patients treated with rituximab and bendamustine (another cancer medicine). 
Druga študija s 389 vsaj enkrat predhodno zdravljenimi bolniki s KLL je pokazala, da je bilo ob zdravljenju z zdravilom Venclixto in rituksimabom obdobje brez bolezni ali brez njenega poslabšanja (podaljševanje časa preživetja brez napredovanja bolezni) daljše kot pri bolnikih, ki so se zdravili s rituksimabom in bendamustinom (drugo zdravilo proti raku).
Venclyxto must not be used with medicines known as ‘strong CYP3A inhibitors' during the early stages of treatment and must also not be used with St. John's wort (a herbal preparation used to treat anxiety and depression). 
Zdravilo Venclyxto se v zgodnjih fazah zdravljenja ne sme uporabljati skupaj z zdravili, znanimi kot močni zaviralci CYP3A, in se prav tako ne sme uporabljati sočasno s šentjanževko (pripravkom rastlinskega izvora za zdravljenje anksioznosti in depresije).
The active substance in Venclyxto, venetoclax, attaches to a protein called Bcl-2. 
Učinkovina v zdravilu Venclyxto, venetoklaks, se veže na beljakovino Bcl-2.
What are the risks associated with Venclyxto? 
Kakšna tveganja so povezana z zdravilom Venclyxto?
What benefits of Venclyxto have been shown in studies? 
Kakšne koristi je zdravilo Venclyxto izkazalo v študijah?
Venclyxto is a cancer medicine used to treat adults with a blood cancer known as chronic lymphocytic leukaemia (CLL). 
Venclyxto je zdravilo za zdravljenje krvnega raka, znanega kot kronična limfocitna levkemija (KLL), pri odraslih bolnikih.
Studies have shown that a high proportion of patients have their cancer cells partially or completely cleared following treatment with Venclyxto on its own. 
Študije so pokazale, da so rakave celice pri velikem deležu bolnikov po zdravljenju samo z zdravilom Venclyxto delno ali popolnoma izginile.
When used in combination with rituximab, Venclyxto was shown to prolong the time patients lived without their disease getting worse. 
Zdravilo Venclixto v kombinaciji z rituksimabom je dokazano podaljšalo čas preživetja bolnikov brez napredovanja bolezni.
Other information about Venclyxto 
Druge informacije o zdravilu Venclyxto:
The most common side effects with Venclyxto used on its own (seen in more than 1 in 5 people) are low levels of neutrophils (a type of white blood cell), diarrhoea, nausea, anaemia (low red blood cell counts), nose and throat infection and tiredness. 
Najpogostejši neželeni učinki zdravila Venclyxto (ki so se pojavili pri več kot 1 bolniku od 5) so zmanjšano število nevtrofilcev (vrste belih krvnih celic), driska, navzea, anemija (nizke ravni rdečih krvnih celic), okužba nosu in grla ter utrujenost.
The most common serious side effects (seen in more than 2 in 100 people) in patients receiving Venclyxto in combination with rituximab or on its own are pneumonia (lung infection), fever associated with reduced neutrophils and tumour lysis syndrome (a complication caused by breakdown of cancer cells). 
Najpogostejši resni neželeni učinki (ki so se pojavili pri več kot 2 bolnikih od 100) pri bolnikih, ki so se zdravili z zdravilom Venclyxto v kombinaciji z rituksimabom, so pljučnica (okužba pljuč), povišana telesna temperatura, povezana z znižanimi vrednostmi nevtrofilcev, in sindrom tumorske lize (zaplet, ki ga povzroča razgradnja rakavih celic).
Studies showed patients with particular genetic mutations (17p deletion or TP53 mutations) that make them unsuitable for chemo-immunotherapy responding well to Venclyxto used on its own. 
Študije kažejo, da se bolniki z določenimi genskimi mutacijami (delecijo 17p ali mutacijami TP53), zaradi katerih so neprimerni za kemoimunoterapijo, na zdravljenje dobro odzovejo.
The most common side effects when Venclyxto is used with rituximab are low level of neutrophils, diarrhoea and nose and throat infection. 
Najpogostejši neželeni učinki zdravila Venclyxto v kombinaciji s rituksimabom so zmanjšano število nevtrofilcev, driska ter okužba nosu in grla.
For the full list of side effects with Venclyxto, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Venclyxto, glejte navodilo za uporabo.
Venclyxto contains that active substance venetoclax. 
Zdravilo Venclyxto vsebuje zdravilno učinkovino venetoklaks.
How is Venclyxto used? 
Kako se zdravilo Venclyxto uporablja?
Patients should have taken Venclyxto at the daily dose of 400 mg for 7 days before starting therapy with rituximab. 
Kadar se zdravilo Venclyxto uporablja v kombinaciji z rituksimabom, je priporočen odmerek tega zdravila 400 mg enkrat na dan. Bolniki naj bi sedem dni jemali 400-miligramski dnevni odmerek zdravilaVenclyxto, preden začnejo zdravljenje z rituksimabom.
How does Venclyxto work? 
Kako zdravilo Venclyxto deluje?
Safety studies have shown that the strain is safe for turkeys. 
Študije varnosti so pokazale, da je sev varen za purane.
For further information see the summary of product characteristics. 
Za več informacij glejte povzetek glavnih značilnosti zdravila.
However, precautionary measures must be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys. 
Kljub temu je treba upoštevati previdnostne ukrepe, da se prepreči neposreden ali posreden stik med cepljenimi piščanci in purani.
The full EPAR for Vectormune ND can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila Vectormune ND je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
In the future if the animals are exposed to a similar virus and/or to a virus expressing a similar fusion protein, the immune system will be able to respond more quickly. 
Če so živali pozneje izpostavljene podobnemu virusu in/ali virusu, ki izraža podoben fuzijski protein, se lahko imunski sistem nanj hitreje odzove.
This is a summary of the European public assessment report (EPAR) for Vectormune ND. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Vectormune ND.
The European Commission granted a marketing authorisation valid throughout the EU for Vectormune ND on 8 September 2015. 
Evropska komisija je dovoljenje za promet z zdravilom Vectormune ND, veljavno po vsej Evropski uniji, izdala 8. septembra 2015.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Vectormune ND's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Vectormune ND večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The vaccine protects against a type of Marek disease virus that can cause visible infection. 
Cepivo ščiti pred tisto vrsto virusa Marekove bolezni, ki lahko povzroči vidno okužbo.
As the vaccine is stored in liquid nitrogen, it is important that any handling is done by appropriately trained personnel in a well-ventilated area and that precautions are taken when preparing the vaccine. 
Cepivo se shranjuje v tekočem dušiku, zato je pomembno, da z njim rokuje usposobljeno osebje v dobro prezračevanem prostoru in da se pri pripravi cepiva upoštevajo previdnostni ukrepi.
ND is a viral infection of chickens which causes gasping and coughing, nervous signs (drooping wings, twisting of the head and neck, circling and paralysis), swelling of the tissues around the eyes and neck, greenish watery diarrhoea and reduced egg production. 
Atipična kokošja kuga je virusna okužba pri piščancih, ki povzroča sopenje in kašelj, znake obolenja živcev (povešena krila, obračanje glave in vratu, kroženje in paralizo), otekanje tkiv okoli oči ter vratu, zelenkasto vodeno drisko in zmanjšano nesnost.
Two field studies were conducted in around 120,000 broiler chickens to evaluate the effects of the vaccine. 
Za ocenjevanje učinkov cepiva so izvedli dve terenski študiji pri približno 120 000 pitovnih piščancih.
Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body. 
Piščanci se okužijo v zgodnjem življenjskem obdobju z vdihavanjem prhljaja (delčkov odpadle kože), ki vsebuje virus, ki je lahko kužen še več mesecev po tem, ko odpade s telesa.
The withdrawal period for meat and eggs from chickens treated with Vectormune ND is ‘zero' days, which means that there is no mandatory waiting time. 
Karenca za meso in jajca piščancev, zdravljenih z zdravilom Vectormune ND, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
The vaccine can be given to one-day-old chicks as a single injection under the skin or directly into 18-day-old eggs containing embryos (unhatched developing chicks). 
Cepivo se lahko uporablja pri en dan starih piščancih v obliki enkratnega injiciranja pod kožo ali neposrednega injiciranja v 18 dni stara jajca, ki vsebujejo zarodke (še ne izvaljene piščance v razvoju).
Other information about Vectormune ND 
Druge informacije o zdravilu Vectormune ND
Vectormune ND is available as a suspension and solvent to be made into a suspension for injection and can only be obtained with a prescription. 
Zdravilo Vectormune ND je na voljo v obliki suspenzije in vehikla za pripravo suspenzije za injiciranje, njegovo predpisovanje in izdaja pa je le na recept.
When Vectormune ND is given to chickens or eggs, the animals' immune system recognises the virus as ‘foreign' and makes antibodies against it. 
Ko piščance ali jajca cepimo s cepivom Vectormune ND, imunski sistem živali prepozna virus kot „tujek“ in začne proti njemu tvoriti protitelesa.
What are the risks associated with Vectormune ND? 
Kakšna tveganja so povezana z zdravilom Vectormune ND?
What is Vectormune ND and what is it used for? 
Kaj je zdravilo Vectormune ND in za kaj se uporablja?
Since no natural outbreaks of ND and MD occurred the chickens were challenged (exposed to infection) in the laboratory. 
Ker ni bilo nobenega naravnega izbruha atipične kokošje kuge in Marekove bolezni, so piščance okužbi izpostavili v laboratoriju.
What benefits of Vectormune ND have been shown in studies? 
Kakšne koristi je zdravilo Vectormune ND izkazalo v študijah?
For MD protection starts at one week of age and lasts for the risk period of infection with MD. 
Zaščita proti Marekovi bolezni se razvije pri enem tednu starosti in traja celotno obdobje tveganja za okužbo z Marekovo boleznijo.